JSPRW (Japer Therapeutics, Inc. Warrants)
Insider Trading Activity
Every open-market purchase and sale reported by JSPRW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-10 | Jeetinder Singh Mahal | CEO and President | A | — | — |
| 2026-01-05 | HERB CROSS | Chief Financial Officer | A | — | — |
| 2026-01-05 | RON MARTELL | President, CEO and Director | A | — | — |
| 2026-01-05 | Jeetinder Singh Mahal | Chief Operating Officer | A | — | — |
| 2025-09-24 | RON MARTELL | President and CEO | Buy | — | — |
| 2025-09-24 | Judith Anne Shizuru | Director | Buy | — | — |
| 2025-09-24 | Svetlana Lucas | Director | Buy | — | — |
| 2025-09-24 | THOMAS G WIGGANS | Director | Buy | — | — |
| 2025-07-03 | Chris Nolet | Director | A | — | — |
| 2025-07-03 | Judith Anne Shizuru | Director | A | — | — |
| 2025-07-03 | KURT VON EMSTER | Director | A | — | — |
| 2025-07-03 | THOMAS G WIGGANS | Director | A | — | — |
| 2025-07-03 | Svetlana Lucas | Director | A | — | — |
| 2025-07-03 | Scott C. Brun | Director | A | — | — |
| 2025-07-03 | Vishal Kapoor | Director | A | — | — |
| 2025-06-06 | RON MARTELL | President and CEO | A | — | — |
| 2025-06-06 | Jeetinder Singh Mahal | Chief Operating Officer | A | — | — |
| 2025-06-06 | Edwin Jonathan Tucker | Chief Medical Officer | A | — | — |
| 2025-06-06 | HERB CROSS | Chief Financial Officer | A | — | — |
| 2025-02-18 | RON MARTELL | President, CEO and Director | A | — | — |
| 2025-02-18 | Jeetinder Singh Mahal | Chief Operating Officer | A | — | — |
| 2025-02-18 | HERB CROSS | Chief Financial Officer | A | — | — |
| 2025-02-18 | Edwin Jonathan Tucker | Chief Medical Officer | A | — | — |
| 2024-12-12 | Jeetinder Singh Mahal | Chief Operating Officer | MIXED | — | — |
| 2024-09-12 | Jeetinder Singh Mahal | Chief Operating Officer | MIXED | — | — |
| 2024-06-20 | Svetlana Lucas | Director | A | — | — |
| 2024-06-12 | Jeetinder Singh Mahal | Chief Operating Officer | MIXED | — | — |
| 2024-06-12 | RON MARTELL | President, CEO and Director | A | — | — |
| 2024-06-10 | Chris Nolet | Director | A | — | — |
| 2024-06-10 | Edwin Jonathan Tucker | Chief Medical Officer | A | — | — |
| 2024-06-10 | Vishal Kapoor | Director | A | — | — |
| 2024-06-10 | Judith Anne Shizuru | Director | A | — | — |
| 2024-06-10 | Anna Louise French | Director | A | — | — |
| 2024-06-10 | Scott C. Brun | Director | A | — | — |
| 2024-06-10 | KURT VON EMSTER | Director | A | — | — |
| 2024-06-10 | THOMAS G WIGGANS | Director | A | — | — |
| 2024-03-12 | Jeetinder Singh Mahal | Chief Operating Officer | MIXED | — | — |
| 2024-02-20 | RON MARTELL | President, CEO and Director | A | — | — |
| 2024-02-20 | Edwin Jonathan Tucker | Chief Medical Officer | A | — | — |
| 2024-02-20 | Jeetinder Singh Mahal | Chief Operating Officer | A | — | — |
| 2024-02-20 | HERB CROSS | Chief Financial Officer | A | — | — |
| 2024-02-12 | LLP Abingworth | 10%+ Owner | Buy | — | — |
| 2024-02-09 | Velan Capital Master Fund LP | — | Buy | — | — |
| 2023-11-30 | THOMAS G WIGGANS | Director | Buy | — | — |
| 2023-11-22 | THOMAS G WIGGANS | Director | Buy | — | — |
| 2023-11-20 | THOMAS G WIGGANS | Director | Buy | — | — |
| 2023-11-02 | THOMAS G WIGGANS | Director | A | — | — |
| 2023-10-13 | RON MARTELL | President, CEO & Director | F | — | — |
| 2023-10-13 | Jeetinder Singh Mahal | Chief Operating Officer | F | — | — |
| 2023-10-13 | William Lis | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,761,891 | — |
| — | 10%+ Owner | 8,519,648 | — |
| — | 10%+ Owner | 4,549,606 | — |
| — | — | 2,300,000 | — |
| — | — | 2,300,000 | — |
| — | 10%+ Owner | 2,300,000 | — |
| — | — | 2,300,000 | — |
| — | — | 1,188,500 | — |
| — | 10%+ Owner | 1,066,189 | — |
| — | Director | 156,901 | — |
| — | President, CEO and Director | 74,118 | — |
| — | Director | 53,521 | — |
| — | Director | 46,000 | — |
| — | Director | 32,500 | — |
| — | CEO and President | 25,009 | — |
| — | Director | 24,500 | — |
| — | Director | 23,750 | — |
| — | Director | 21,175 | — |
| — | Director | 20,000 | — |
| — | Chief Medical Officer | 400 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JSPRW quote page; the site-wide leaderboard is on the insider transactions hub.